What the DMCCA means for aesthetic clinic marketing

The Digital Markets, Competition and Consumers Act 2024 came into force in April 2025. For most aesthetic clinics, it passed without comment. That is a problem — because the enforcement environment it created is materially different from the one that existed before.

What the Act is

The DMCCA is a piece of primary legislation that covers three distinct areas: digital markets regulation, competition law reform, and consumer protection. For aesthetic clinics, only the third is directly relevant — but it is significant enough on its own terms to require attention.

The consumer protection provisions replace and strengthen the Consumer Protection from Unfair Trading Regulations 2008. They define unfair commercial practices with greater specificity, include explicit provisions on drip pricing and urgency tactics, and — most importantly — change who can enforce them and how.

The enforcement shift that matters

Under the pre-2025 framework, the Competition and Markets Authority could only take enforcement action against businesses through the courts. This made enforcement slow, expensive, and practically limited to the most egregious cases. The DMCCA changed that. The CMA can now investigate and impose penalties directly, without needing a court order.

The financial exposure is substantial. Penalties for non-compliance can reach up to 10% of worldwide annual turnover. For a London aesthetic clinic generating £2 million a year, that is a potential penalty of £200,000. For a multi-site operation, the numbers are larger. These are not theoretical figures — they represent the statutory ceiling that Parliament has explicitly authorised.

What the Act covers — and why aesthetic clinics are squarely in scope

The DMCCA's consumer protection provisions apply to any business engaging in commercial practices directed at consumers. This is not limited to advertising in the narrow sense. It covers the entire decision-making journey — from the first point of contact to the moment a consumer commits to a procedure.

For aesthetic clinics, this means the following are in scope: website content, social media posts, paid advertising, email communications, in-clinic consultations, pricing presentations, booking processes, and any urgency or scarcity messaging used at any stage. The test is whether a commercial practice could mislead a consumer, or whether it applies pressure that impairs their ability to make a free and informed decision.

Several common practices in aesthetic clinic marketing fail this test. Countdown timers that have no basis in genuine scarcity. "Only three spaces remaining" notifications that reset automatically. Promotional pricing presented as time-limited when it is effectively permanent. Testimonials and results imagery that imply typical outcomes. These are not edge cases — they appear regularly across clinic websites and social channels.

Urgency tactics and the "cooling off" principle

The DMCCA is explicit about commercial practices that exploit time pressure. Artificial urgency — creating a false impression that an offer is about to expire, or that availability is limited when it is not — is classified as a misleading commercial practice. This is not new as a principle, but the enforcement mechanism that backs it up now is new.

The cooling-off principle is directly relevant here. The Royal College of Surgeons and the JCCP both recommend a minimum cooling-off period between consultation and treatment for cosmetic procedures. Marketing that actively works against this principle — by creating pressure to decide quickly — is both clinically problematic and now a more concrete legal risk. The DMCCA's provisions on pressure selling reinforce what responsible clinical governance already requires.

Pricing transparency and drip pricing

Drip pricing is one of the Act's specific targets. It describes the practice of advertising an initial price that does not reflect what the consumer will actually pay once mandatory charges are added progressively through the booking process. In the context of aesthetic clinics, this applies to how consultation fees, anaesthetic costs, facility fees, and post-treatment requirements are presented alongside headline procedure pricing.

The standard the Act sets is that the total price a consumer will pay — or a clear explanation of how it will be calculated — must be provided upfront. Presenting a procedure price that excludes necessary associated costs, and revealing those costs only when the consumer is invested in proceeding, is now explicitly within the scope of CMA enforcement.

Claims, testimonials, and result presentation

The DMCCA's provisions on misleading commercial practices apply to any false or deceptive presentation that could affect a consumer's decision. In the context of aesthetic clinics, this bears directly on how results are presented, how testimonials are used, and what claims are made about the likely outcomes of treatment.

A testimonial that describes an exceptional outcome, presented without any indication that this is not a typical result, can constitute a misleading commercial practice under the Act. Before-and-after imagery that has been photographed or processed in a way that overstates typical outcomes carries the same risk. The question is not whether the result shown is genuine — it is whether a consumer encountering that content would form an accurate understanding of what they might typically expect.

What a defensible operation looks like

The DMCCA does not change the underlying principle that honest marketing is both legally compliant and commercially viable. It does change the enforcement environment significantly enough that clinics which have not reviewed their marketing against the new framework are operating with unquantified risk.

A defensible operation is one where the following are in place:

• All published claims are substantiated and the substantiation is documented
• Urgency and scarcity messaging is genuine and verifiable
• Pricing presentations include all mandatory costs or a clear calculation methodology
• Testimonials and results imagery include appropriate context about typical outcomes
• Consent processes and consultation-to-treatment timelines respect the cooling-off principle
• A governance record exists for each piece of marketing content showing the basis on which it was approved

This is not a checklist that can be completed once and filed. It is a system that needs to operate continuously — because marketing content changes, the regulatory environment continues to develop, and the record of compliance needs to be current rather than historical.

Practical steps

If you have not reviewed your marketing against the DMCCA framework, the starting point is a structured audit. This means going through every active marketing channel — website, paid social, Google Ads, email, organic social — and assessing each piece of content against the Act's provisions on misleading practices, urgency tactics, and pricing transparency.

That audit should produce a written record: what was reviewed, what the risks identified were, and what was changed. The record matters because it demonstrates that the business has taken the compliance obligation seriously. In the event of a CMA investigation, a documented governance process is evidence of good faith. Its absence is evidence of the opposite.

The governance infrastructure does not need to be complex. It needs to be consistent, documented, and applied to everything that goes out under the clinic's name. That is the standard the DMCCA environment now requires.